Inflammatix Stock

inflammatix.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $266.57MM

Inflammatix uses molecular diagnostics to read the patient’s immune system to deliver rapid results that improve patient care and reduce major public health burdens.

Register To Buy and Sell Shares

For more details on financing and valuation for Inflammatix, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Inflammatix’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Inflammatix.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Frequently Asked Questions About Inflammatix’s Stock

Can you buy Inflammatix’s stock?
Inflammatix is not publicly traded on NYSE or NASDAQ in the U.S. To buy Inflammatix’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Inflammatix’s stock?
Yes, you can sell stock of a private company like Inflammatix. Forge can help you sell your Inflammatix stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Inflammatix’s stock price?
Inflammatix is a privately held company and therefore does not have a public stock price. However, you may access Inflammatix’s private market stock price with Forge Data.
What is Inflammatix’s stock ticker symbol?
Inflammatix does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Inflammatix Receives Additional $12.1M BARDA Funding for MDx Acute Infection Test, System
The award represents the third tranche of funding from a test development contract worth up to $72 million if all options are exercised.
Updated on: Jun 16, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.